source
- Biohaven signs up to $795 million deal with SK Biopharma to license Kv7 platform and epilepsy assetBiohaven announced a licensing agreement with South Korean SK Biopharma centered on its Kv7 ion channel platform and lead epilepsy candidate opakalim. The deal could deliver up to $795 million, in…
- Turkish antitrust regulator launches probe into Teva for alleged patent manipulation and false claims about rivalsTurkish competition authorities have opened an investigation into Teva Pharmaceutical, the world’s largest generic drugmaker, accusing the company of manipulating the patent system and making misle…